TIDMBIOG

Biotech Growth Trust PLC (The)

10 August 2020

London, UK, 10 August 2020

Edison issues review on The Biotech Growth Trust (BIOG)

The Biotech Growth Trust (BIOG) is managed by Geoff Hsu, who is able to draw on the considerable resources of specialist healthcare investor OrbiMed Capital. While biotech stocks have rallied strongly following the coronavirus-led stock market sell-off earlier in 2020, the manager believes they could have further to go. He is confident that a successful COVID-19 vaccine will be developed and positive fundamentals are supportive for the biotech sector's future performance. Repositioning of BIOG's portfolio during FY20 has been accretive to the trust's returns in recent quarters; it has now outperformed its benchmark NASDAQ Biotechnology index over the past one, three, five and 10 years, and investors have also enjoyed very solid absolute total returns of more than 20% pa over the past decade.

BIOG has an active discount control programme, aiming to limit the discount to a maximum of c 6% in normal market conditions. The trust's current 3.3% share price premium to cum-income NAV compares with a 5.5% to 7.2% range of average discounts over the past one, three, five and 10 years.

Click here to view the full report.

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website .

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Mel Jenner, +44 (0)20 3077 5720

Sarah Godfrey, +44 (0)20 3681 2519

investmenttrusts@edisongroup.com

   Learn more at   www.edisongroup.com   and connect with Edison on: 
   LinkedIn        https://www.linkedin.com/company/edison-group- 
   Twitter           www.twitter.com/Edison_Inv_Res 
   YouTube       www.youtube.com/edisonitv

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAGPURURUPUGCU

(END) Dow Jones Newswires

August 10, 2020 10:12 ET (14:12 GMT)

Biotech Growth (LSE:BIOG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Biotech Growth Charts.
Biotech Growth (LSE:BIOG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Biotech Growth Charts.